Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  7/11/2013
Univ of Pennsylvania
mi
from
Philadelphia, PA
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 7/11/2013
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  7/11/2013
University of Texas- Houston Medical School
mi
from
Houston, TX
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 7/11/2013
University of Texas- Houston Medical School
mi
from
Houston, TX
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  7/11/2013
University of Utah
mi
from
Salt Lake City, UT
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 7/11/2013
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  7/11/2013
Arthritis Northwest
mi
from
Spokane, WA
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 7/11/2013
Arthritis Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  7/11/2013
Medical College of Wisconsin
mi
from
Milwaukee, WI
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Prospective, Randomized, Placebo-controlled, Double-blind, Mutlicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Schemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 7/11/2013
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients
A Multicenter, Prospective Study to Evaluate CLn® BodyWash As An Adjunctive Therapy in Pediatric Subjects With Moderate to Severe, Staphylococcus Aureus Colonized Atopic Dermatitis
Status: Enrolling
Updated:  7/13/2013
Northwestern University Department of Dermatology
mi
from
Chicago, IL
A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients
A Multicenter, Prospective Study to Evaluate CLn® BodyWash As An Adjunctive Therapy in Pediatric Subjects With Moderate to Severe, Staphylococcus Aureus Colonized Atopic Dermatitis
Status: Enrolling
Updated: 7/13/2013
Northwestern University Department of Dermatology
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients
A Multicenter, Prospective Study to Evaluate CLn® BodyWash As An Adjunctive Therapy in Pediatric Subjects With Moderate to Severe, Staphylococcus Aureus Colonized Atopic Dermatitis
Status: Enrolling
Updated:  7/13/2013
University of Texas Medical School in Houston
mi
from
Houston, TX
A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients
A Multicenter, Prospective Study to Evaluate CLn® BodyWash As An Adjunctive Therapy in Pediatric Subjects With Moderate to Severe, Staphylococcus Aureus Colonized Atopic Dermatitis
Status: Enrolling
Updated: 7/13/2013
University of Texas Medical School in Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema
A Double-Blind Pilot Study To Assess The Feasibility of a Larger Study to Assess The Efficacy of A Novel Gel Wash Cleanser Formulated With Sodium Hypochlorite To Reduce Skin Fauna In Patients With Chronic Hand Dermatitis/Atopic Dermatitis.
Status: Enrolling
Updated:  7/13/2013
Ohio State University
mi
from
Gahanna, OH
A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema
A Double-Blind Pilot Study To Assess The Feasibility of a Larger Study to Assess The Efficacy of A Novel Gel Wash Cleanser Formulated With Sodium Hypochlorite To Reduce Skin Fauna In Patients With Chronic Hand Dermatitis/Atopic Dermatitis.
Status: Enrolling
Updated: 7/13/2013
Ohio State University
mi
from
Gahanna, OH
Click here to add this to my saved trials
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated:  7/24/2013
UCSD/Rady Childrens Hospital
mi
from
San Diego, CA
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated: 7/24/2013
UCSD/Rady Childrens Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated:  7/24/2013
Northwestern University
mi
from
Chicago, IL
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated: 7/24/2013
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated:  7/24/2013
Sneeze, Wheeze & Itch Associates LLC
mi
from
Normal, IL
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated: 7/24/2013
Sneeze, Wheeze & Itch Associates LLC
mi
from
Normal, IL
Click here to add this to my saved trials
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated:  7/24/2013
Minnesota Clinical Study Center
mi
from
Fridley, MN
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated: 7/24/2013
Minnesota Clinical Study Center
mi
from
Fridley, MN
Click here to add this to my saved trials
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated:  7/24/2013
Academic Dermatology Associates
mi
from
Albuquerque, NM
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated: 7/24/2013
Academic Dermatology Associates
mi
from
Albuquerque, NM
Click here to add this to my saved trials
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated:  7/24/2013
Dermatology Consulting Services
mi
from
High Point, NC
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated: 7/24/2013
Dermatology Consulting Services
mi
from
High Point, NC
Click here to add this to my saved trials
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated:  7/24/2013
DermResearch, Inc.
mi
from
Austin, TX
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated: 7/24/2013
DermResearch, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated:  7/24/2013
UT-Houston Health Science Center
mi
from
Houston, TX
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated: 7/24/2013
UT-Houston Health Science Center
mi
from
Houston, TX
Click here to add this to my saved trials
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated:  7/24/2013
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age
Status: Enrolling
Updated: 7/24/2013
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Mesa, AZ
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Mesa, AZ
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Riverside, CA
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Riverside, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
San Diego, CA
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Farmington, CT
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Farmington, CT
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Dunedin, FL
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Dunedin, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Orange Park, FL
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Orange Park, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Tampa, FL
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Boston, MA
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Fort Gratiot, MI
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Fort Gratiot, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Sterling Heights, MI
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Sterling Heights, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Omaha, NE
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Henderson, NV
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Chapel Hill, NC
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Winston-Salem, NC
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Pittsburgh, PA
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Nashville, TN
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Norfolk, VA
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  7/31/2013
Clinical Research Facility
mi
from
Seattle, WA
Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa
Clinical Study Protocol M11-810 - PIONEER II A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 7/31/2013
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Questionnaire and Laboratory Data on Vitiligo Vulgaris
Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris
Status: Enrolling
Updated:  8/1/2013
Department of Dermatology, St. Luke's-Roosevelt Hospital Center
mi
from
New York, NY
Questionnaire and Laboratory Data on Vitiligo Vulgaris
Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris
Status: Enrolling
Updated: 8/1/2013
Department of Dermatology, St. Luke's-Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Questionnaire and Laboratory Data on Vitiligo Vulgaris
Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris
Status: Enrolling
Updated:  8/1/2013
Department of Dermatology, Beth Israel Medical Center
mi
from
New York, NY
Questionnaire and Laboratory Data on Vitiligo Vulgaris
Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris
Status: Enrolling
Updated: 8/1/2013
Department of Dermatology, Beth Israel Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Status: Enrolling
Updated:  8/16/2013
Johns Hopkins University
mi
from
Baltimore, MD
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Status: Enrolling
Updated: 8/16/2013
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris
Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris
Status: Enrolling
Updated:  8/21/2013
UCSD Division of Dermatology
mi
from
San Diego, CA
Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris
Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris
Status: Enrolling
Updated: 8/21/2013
UCSD Division of Dermatology
mi
from
San Diego, CA
Click here to add this to my saved trials
Prevalence of Human Papillomavirus in Men Living in the Northern Plains
Prevalence of Human Papillomavirus in Men Living in the Northern Plains
Status: Enrolling
Updated:  9/4/2013
Sanford Health
mi
from
Sioux Falls, SD
Prevalence of Human Papillomavirus in Men Living in the Northern Plains
Prevalence of Human Papillomavirus in Men Living in the Northern Plains
Status: Enrolling
Updated: 9/4/2013
Sanford Health
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
Mobile, AL
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
Hot Springs, AZ
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
Hot Springs, AZ
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
Irvine, CA
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
Irvine, CA
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
Orange Park, FL
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
Orange Park, FL
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
Tampa, FL
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
Carmel, IN
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
Carmel, IN
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
Berlin, NJ
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
Berlin, NJ
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
High Point, NC
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
Portland, OR
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  9/10/2013
Clinical Research Facility
mi
from
College Station, TX
A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis
A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 9/10/2013
Clinical Research Facility
mi
from
College Station, TX
Click here to add this to my saved trials